BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Heimfarth L, Serafini MR, Martins-Filho PR, Quintans JSS, Quintans-Júnior LJ. Drug repurposing and cytokine management in response to COVID-19: A review. Int Immunopharmacol 2020;88:106947. [PMID: 32919216 DOI: 10.1016/j.intimp.2020.106947] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 18.5] [Reference Citation Analysis]
Number Citing Articles
1 Lu LW, Gao Y, Quek S, Foster M, Eason CT, Liu M, Wang M, Chen J, Chen F. The landscape of potential health benefits of carotenoids as natural supportive therapeutics in protecting against Coronavirus infection. Biomedicine & Pharmacotherapy 2022;154:113625. [DOI: 10.1016/j.biopha.2022.113625] [Reference Citation Analysis]
2 Martins-Filho PR, do Nascimento-Júnior EM, Barreto-Alves JA, Fakhouri R, Ferreira LC. Efficacy and safety of nitazoxanide in treating SARS-CoV-2 infection: a systematic review and meta-analysis of blinded, placebo-controlled, randomized clinical trials. Eur J Clin Pharmacol 2022. [PMID: 36066651 DOI: 10.1007/s00228-022-03380-5] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Saha T, Quiñones-Mateu ME, Das SC. Inhaled therapy for COVID-19: Considerations of drugs, formulations and devices. Int J Pharm 2022;624:122042. [PMID: 35868481 DOI: 10.1016/j.ijpharm.2022.122042] [Reference Citation Analysis]
4 Siutkina IP, Khabarov DV, Bulychev PV, Demura AY, Inyoshina AD. Successful treatment of a severe course of coronavirus infection in the obese polymorbid patient after bariatric surgery. Bûll sib med 2022;21:207-211. [DOI: 10.20538/1682-0363-2022-2-207-211] [Reference Citation Analysis]
5 Saha T, Sinha S, Harfoot R, Quiñones-Mateu ME, Das SC. Manipulation of Spray-Drying Conditions to Develop an Inhalable Ivermectin Dry Powder. Pharmaceutics 2022;14:1432. [PMID: 35890327 DOI: 10.3390/pharmaceutics14071432] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Awosanya OD, Dadwal UC, Imel EA, Yu Q, Kacena MA. The Impacts of COVID-19 on Musculoskeletal Health. Curr Osteoporos Rep 2022. [PMID: 35723777 DOI: 10.1007/s11914-022-00734-x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Arsène S, Couty C, Faddeenkov I, Go N, Granjeon-Noriot S, Šmít D, Kahoul R, Illigens B, Boissel JP, Chevalier A, Lehr L, Pasquali C, Kulesza A. Modeling the disruption of respiratory disease clinical trials by non-pharmaceutical COVID-19 interventions. Nat Commun 2022;13:1980. [PMID: 35418135 DOI: 10.1038/s41467-022-29534-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Rabiu Abubakar A, Ahmad R, Rowaiye AB, Rahman S, Iskandar K, Dutta S, Oli AN, Dhingra S, Tor MA, Etando A, Kumar S, Irfan M, Gowere M, Chowdhury K, Akter F, Jahan D, Schellack N, Haque M. Targeting Specific Checkpoints in the Management of SARS-CoV-2 Induced Cytokine Storm. Life 2022;12:478. [DOI: 10.3390/life12040478] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Sengar M, Ranganathan P. The Interplay between COVID-19 and Cancer: Challenges and Perspectives. Indian J Med Paediatr Oncol. [DOI: 10.1055/s-0042-1743128] [Reference Citation Analysis]
10 Kountouras J, Gialamprinou D, Kotronis G, Papaefthymiou A, Economidou E, Soteriades ES, Vardaka E, Chatzopoulos D, Tzitiridou-chatzopoulou M, Papazoglou DD, Doulberis M. Ofeleein i mi Vlaptin—Volume II: Immunity Following Infection or mRNA Vaccination, Drug Therapies and Non-Pharmacological Management at Post-Two Years SARS-CoV-2 Pandemic. Medicina 2022;58:309. [DOI: 10.3390/medicina58020309] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 El-Sayed EM, Ibrahim KS. Ameliorating effects of probiotics on alterations in iron homeostasis and inflammation in COVID-19. Mol Biol Rep 2022. [PMID: 35169998 DOI: 10.1007/s11033-022-07226-2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Bonnet R, Mariault L, Peyron JF. Identification of potentially anti-COVID-19 active drugs using the connectivity MAP. PLoS One 2022;17:e0262751. [PMID: 35085325 DOI: 10.1371/journal.pone.0262751] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Ng RW, Wong C, Lui GC, Tso EY, Chen Z, Tsang OT, Boon SS, Lai CK, Fung KS, Yeung AC, Ho WC, Hui DS, Chan PK, Chan JM. Case series of HIV SARS-CoV-2 co-infection in Chinese adults. Journal of Clinical Virology Plus 2022;2:100062. [DOI: 10.1016/j.jcvp.2022.100062] [Reference Citation Analysis]
14 Danquah J, Mante PK. Post-illness anxiety, depression and PTSD symptoms in COVID-19 survivors. International Journal of Mental Health. [DOI: 10.1080/00207411.2022.2028057] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
15 Anantharaj A, Gujjar S, Verma N, Khan NA, Shaman H, Sharanabasava P, Das A, Pandey R, Pandey AK, Medigeshi GR. Resolution of viral load in mild COVID-19 patients is associated with both innate and adaptive immune responses. J Clin Virol 2021;146:105060. [PMID: 34971849 DOI: 10.1016/j.jcv.2021.105060] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
16 Arsène S, Couty C, Faddeenkov I, Go N, Granjeon-noriot S, Šmít D, Kahoul R, Illigens B, Boissel J, Chevalier A, Lehr L, Pasquali C, Kulesza A. Viral kinetic modeling and clinical trial simulation predicts disruption of respiratory disease trials by non-pharmaceutical COVID-19 interventions.. [DOI: 10.1101/2021.11.09.21266145] [Reference Citation Analysis]
17 Majeed M, Noor T. The Extrapulmonary Manifestations of SARS-CoV-2. TOCOVIDJ 2021;1:80-92. [DOI: 10.2174/2666958702101010080] [Reference Citation Analysis]
18 Pushparaj PN, Abdulkareem AA, Naseer MI. Identification of Novel Gene Signatures using Next-Generation Sequencing Data from COVID-19 Infection Models: Focus on Neuro-COVID and Potential Therapeutics. Front Pharmacol 2021;12:688227. [PMID: 34531741 DOI: 10.3389/fphar.2021.688227] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
19 Martins-Filho PR, Ferreira LC, Heimfarth L, Araújo AAS, Quintans-Júnior LJ. Efficacy and safety of hydroxychloroquine as pre-and post-exposure prophylaxis and treatment of COVID-19: A systematic review and meta-analysis of blinded, placebo-controlled, randomized clinical trials. Lancet Reg Health Am 2021;2:100062. [PMID: 34485970 DOI: 10.1016/j.lana.2021.100062] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 11.0] [Reference Citation Analysis]
20 Das DK, Kumar A, Vashistha VK. Advancement in Nanomaterials for Rapid Sensing, Diagnosis, and Prevention of COVID-19. Nano LIFE 2021;11:2130007. [DOI: 10.1142/s1793984421300077] [Reference Citation Analysis]
21 Garg SS, Sharma A, Gupta J. Immunomodulation and immunotherapeutics of COVID-19. Clin Immunol 2021;231:108842. [PMID: 34461289 DOI: 10.1016/j.clim.2021.108842] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
22 Sunkara H, Dewan SMR. Coronavirus disease-2019: A review on the disease exacerbation via cytokine storm and concurrent management. Int Immunopharmacol 2021;99:108049. [PMID: 34426104 DOI: 10.1016/j.intimp.2021.108049] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
23 Abou-El-Naga IF, Gomaa MM, ElAchy SN. Effect of HIV aspartyl protease inhibitors on experimental infection with a cystogenic Me49 strain of Toxoplasma gondii. Pathog Glob Health 2021;:1-12. [PMID: 34420500 DOI: 10.1080/20477724.2021.1967628] [Reference Citation Analysis]
24 Dabholkar N, Gorantla S, Dubey SK, Alexander A, Taliyan R, Singhvi G. Repurposing methylene blue in the management of COVID-19: Mechanistic aspects and clinical investigations. Biomed Pharmacother 2021;142:112023. [PMID: 34399199 DOI: 10.1016/j.biopha.2021.112023] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
25 DeJong C, Spinelli MA, Okochi H, Gandhi M. Tenofovir-based PrEP for COVID-19: an untapped opportunity? AIDS 2021;35:1509-11. [PMID: 33710026 DOI: 10.1097/QAD.0000000000002877] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
26 Martins-filho PR, Ferreira LC, Heimfarth L, de Souza Araújo AA, Quintans-júnior LJ. Efficacy and safety of hydroxychloroquine as pre-and post-exposure prophylaxis and treatment of COVID-19. Systematic review and meta-analysis of blinded, placebo-controlled, randomized clinical trials.. [DOI: 10.1101/2021.06.12.21258831] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
27 Karimi A, Rafiei Tabatabaei S, Shiva F, Hoseinialfatemi SM. COVID-19 or Influenza, or Both? A Comparison and Algorithmic Approach to Management. Jundishapur J Microbiol 2021;13. [DOI: 10.5812/jjm.112121] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Saygili E, Yildiz-Ozturk E, Green MJ, Ghaemmaghami AM, Yesil-Celiktas O. Human lung-on-chips: Advanced systems for respiratory virus models and assessment of immune response. Biomicrofluidics 2021;15:021501. [PMID: 33791050 DOI: 10.1063/5.0038924] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
29 Abouelela ME, Assaf HK, Abdelhamid RA, Elkhyat ES, Sayed AM, Oszako T, Belbahri L, El Zowalaty AE, Abdelkader MSA. Identification of Potential SARS-CoV-2 Main Protease and Spike Protein Inhibitors from the Genus Aloe: An In Silico Study for Drug Development. Molecules 2021;26:1767. [PMID: 33801151 DOI: 10.3390/molecules26061767] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 17.0] [Reference Citation Analysis]
30 Ali AH, Sudi S, Shi-Jing N, Hassan WRM, Basir R, Agustar HK, Embi N, Sidek HM, Latip J. Dual Anti-Malarial and GSK3β-Mediated Cytokine-Modulating Activities of Quercetin Are Requisite of Its Potential as a Plant-Derived Therapeutic in Malaria. Pharmaceuticals (Basel) 2021;14:248. [PMID: 33803419 DOI: 10.3390/ph14030248] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
31 Mai E, Percopo CM, Limkar AR, Sek AC, Ma M, Rosenberg HF. Respiratory Epithelial Cells Respond to Lactobacillus plantarum but Provide No Cross-Protection against Virus-Induced Inflammation. Viruses 2020;13:E2. [PMID: 33374950 DOI: 10.3390/v13010002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
32 Soni DK, Cabrera-luque J, Kar S, Sen C, Devaney J, Biswas R. Suppression of miR-155 attenuates lung cytokine storm induced by SARS-CoV-2 infection in human ACE2-transgenic mice.. [DOI: 10.1101/2020.12.17.423130] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
33 Lo Bianco G, Di Pietro S, Mazzuca E, Imburgia A, Tarantino L, Accurso G, Benenati V, Vernuccio F, Bucolo C, Salomone S, Riolo M. Multidisciplinary Approach to the Diagnosis and In-Hospital Management of COVID-19 Infection: A Narrative Review. Front Pharmacol 2020;11:572168. [PMID: 33362541 DOI: 10.3389/fphar.2020.572168] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
34 Anantharaj A, Gujjar S, Kumar S, Verma N, Wangchuk J, Khan NA, Panwar A, Kanakan A, A V, Vasudevan JS, Das A, Pandey AK, Pandey R, Medigeshi GR. Kinetics of viral load, immunological mediators and characterization of a SARS-CoV-2 isolate in mild COVID-19 patients during acute phase of infection.. [DOI: 10.1101/2020.11.05.20226621] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
35 Mousavi SZ, Rahmanian M, Sami A. A connectivity map-based drug repurposing study and integrative analysis of transcriptomic profiling of SARS-CoV-2 infection. Infect Genet Evol 2020;86:104610. [PMID: 33130005 DOI: 10.1016/j.meegid.2020.104610] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]